Prostate Cancer
Conditions
Brief summary
A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer
Detailed description
1. To perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia marker gene expression in human prostate cancers 2. To characterize expression and hypoxia/HIF-responsiveness of myoglobin, cytoglobin, α-hemoglobin in prostate tumors and cell lines 3. To identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancers
Interventions
DEVICEPimonidazol
0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
Sponsors
University of Zurich
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the Department of Urology, University Hospital of Zurich * Written informed consent
Exclusion criteria
* Metastatic prostate cancer * Contraindications to the class of investigational product under study, e.g. known hypersensitivity or allergy to the investigational product * Severe heart or lung disease * Severe liver or kidney dysfunction * Severe stridor * Distant metastases * Concurrent treatment for other malignant disease * Prior hormonal therapy or radiotherapy
Countries
Switzerland
Contacts
Primary Contact01 Studienregister MasterAdmins
Outcome results
None listed